DSpace コレクション: 2015-092015-09http://hdl.handle.net/2433/2006532024-03-28T08:03:29Z2024-03-28T08:03:29Z腎摘除術後創部近傍に発生した,再発腎細胞癌との鑑別を要したDesmoid腫瘍の1例大竹, 慎二南村, 和宏藤川, 敦澤田, 卓人太田, 純一森山, 正敏林, 宏行http://hdl.handle.net/2433/2008142021-09-15T10:16:53Z2015-09-30T00:00:00Zタイトル: 腎摘除術後創部近傍に発生した,再発腎細胞癌との鑑別を要したDesmoid腫瘍の1例
著者: 大竹, 慎二; 南村, 和宏; 藤川, 敦; 澤田, 卓人; 太田, 純一; 森山, 正敏; 林, 宏行
抄録: A 71-year-old man with a right renal tumor underwent nephrectomy. The procedure was converted from laparoscopy to open surgery due to profound bleeding from the renal vein. Pathological diagnosis was clear cell carcinoma G2pT3b v1 ly1 INFα. Three years after surgery, a 5 cm tumor in the abdominal wall was found on computed tomography (CT). A mild uptake was shown on positron emission tomography/CT and as the tumor was located near the surgical wound, recurrence of the renal cell carcinoma was suspected. However, desmoid tumor was suggested by the pathological examination of the tumor biopsy. En-bloc resection of the mass was carried out and the pathological examination showed an array of proliferating and tangling atypical spindle-shaped tumor cells. Immunohistochemical staining of the tumor cells was positive for vimentin, but negative for CD34, c-kit, and s100. Pathological diagnosis was desmoid tumor. There has been no recurrence so far. Desmoid tumor, despite its extremely low incidence, should be considered in a postoperative neoplasm.2015-09-30T00:00:00Z転移性腎細胞癌に対してソラフェニブ内服治療中に心筋梗塞を発症した3例髙木, 公暁髙井, 学河田, 啓堀江, 憲吾菊地, 美奈加藤, 卓水谷, 晃輔清家, 健作土屋, 朋大安田, 満横井, 繁明仲野, 正博牛越, 博昭宮崎, 龍彦出口, 隆http://hdl.handle.net/2433/2008152021-09-15T10:16:53Z2015-09-30T00:00:00Zタイトル: 転移性腎細胞癌に対してソラフェニブ内服治療中に心筋梗塞を発症した3例
著者: 髙木, 公暁; 髙井, 学; 河田, 啓; 堀江, 憲吾; 菊地, 美奈; 加藤, 卓; 水谷, 晃輔; 清家, 健作; 土屋, 朋大; 安田, 満; 横井, 繁明; 仲野, 正博; 牛越, 博昭; 宮崎, 龍彦; 出口, 隆
抄録: Sorafenib is a tyrosine kinase inhibitor (TKI) of the vascular endothelial growth factor receptor (VEGFR) used for advanced renal cell carcinoma. Treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal cell carcinoma. However, in spite of its therapeutic efficacy, sorafenib causes a wide range of adverse events. Cardiovascular adverse events have been observed when sorafenib was used with targeted agents. Although these adverse events like hypertension, reduced left ventricular ejection fraction, cardiac ischemia or infarction were manageable with standard medical therapies in most cases, some had a poor clinical outcome. We report three cases of acute myocardial infarction associated with sorafenib in patients with metastatic renal cell carcinoma.2015-09-30T00:00:00Z対側腎再発に対して体外腎部分切除術および自家腎移植を施行した有転移性腎癌の1例尾張, 拓也吉田, 克法米田, 龍生岩本, 崇史堀俊, 太森澤, 洋介桑田, 真臣三宅, 牧人鳥本, 一匡青木, 勝也田中, 宣道藤本, 清秀http://hdl.handle.net/2433/2008132021-09-15T10:16:53Z2015-09-30T00:00:00Zタイトル: 対側腎再発に対して体外腎部分切除術および自家腎移植を施行した有転移性腎癌の1例
著者: 尾張, 拓也; 吉田, 克法; 米田, 龍生; 岩本, 崇史; 堀俊, 太; 森澤, 洋介; 桑田, 真臣; 三宅, 牧人; 鳥本, 一匡; 青木, 勝也; 田中, 宣道; 藤本, 清秀
抄録: A 68-year-old man underwent radical nephrectomy for renal cell carcinoma of the right kidney 12 years ago. He was diagnosed as having a recurrent tumor of the contralateral kidney and a single metastatic pulmonary lesion by diagnostic imaging on the annual checkup. He visited us in order to receive nephron sparing surgery. Since the preoperative abdominal computed tomography showed tumor thrombus invading intothe intrarenal vein, ex vivo partial nephrectomy and auto-transplantation was performed. Although he received transit hemodialysis during the postoperative 10 days, his renal function, thereafter became stable without hemodialysis. Eighty-seven days later he underwent right lower lobectomy. At postoperative 6 months he has no local recurrence or distant metastasis and maintains well-preserved renal function.2015-09-30T00:00:00Zジャックナイフ体位で前立腺部分切除を施行した進行直腸癌の1例村上, 薫木村, 博子中嶋, 正和青山, 輝義河本, 泉橋村, 孝幸http://hdl.handle.net/2433/2008122021-09-15T10:16:53Z2015-09-30T00:00:00Zタイトル: ジャックナイフ体位で前立腺部分切除を施行した進行直腸癌の1例
著者: 村上, 薫; 木村, 博子; 中嶋, 正和; 青山, 輝義; 河本, 泉; 橋村, 孝幸
抄録: A 72-year-old man was diagnosed with advanced rectal cancer possibly involving the prostate on magnetic resonance imaging (MRI) findings. Following neoadjuvant chemoradiotherapy (CRT), he underwent curative surgery. Confirming negative surgical margin through intraoperative pathological evaluation, colorectectomy with partial prostatectomy was performed in the jack-knife position. No evidence of local recurrence of the tumor was observed one year after surgery without symptoms of the urinary tract. Partial prostatectomy is a choice to be taken into account in the treatment of advanced rectal cancer achieving both the good surgical outcome and the patient’s quality of life (QOL).2015-09-30T00:00:00Z